Cargando…

Targeting the ATR-CHK1 Axis in Cancer Therapy

Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of AT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rundle, Stuart, Bradbury, Alice, Drew, Yvette, Curtin, Nicola J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447951/ https://www.ncbi.nlm.nih.gov/pubmed/28448462 http://dx.doi.org/10.3390/cancers9050041

Ejemplares similares

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
por: Bradbury, Alice, et al.
Publicado: (2022)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
por: Ahmed, Salman, et al.
Publicado: (2022)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
por: Gralewska, Patrycja, et al.
Publicado: (2020)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer
por: Doerr, Fabian, et al.
Publicado: (2017)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

Critical role of SMG7 in activation of the ATR-CHK1 axis in response to genotoxic stress
por: Ho, Kathleen, et al.
Publicado: (2021)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors()
por: Job, Albert, et al.
Publicado: (2018)

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)

miR-107 Activates ATR/Chk1 Pathway and Suppress Cervical Cancer Invasion by Targeting MCL1
por: Zhou, Chengyan, et al.
Publicado: (2014)

Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer
por: Batnini, Kalil, et al.
Publicado: (2022)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
por: Ma, Hanhui, et al.
Publicado: (2013)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer
por: Guo, Yuchen, et al.
Publicado: (2021)

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
por: Chen, Sansan, et al.
Publicado: (2016)

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
por: Nie, Sipei, et al.
Publicado: (2021)

PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors
por: Göder, Anja, et al.
Publicado: (2023)

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors
por: Golder, Anya, et al.
Publicado: (2022)

CTP sensing and Mec1(ATR)-Rad53(CHK1/CHK2) mediate a two-layered response to inhibition of glutamine metabolism
por: Ajazi, Arta, et al.
Publicado: (2022)

Multiple ATR-Chk1 Pathway Proteins Preferentially Associate with Checkpoint-Inducing DNA Substrates
por: Yilmaz, Seçil, et al.
Publicado: (2011)

Correction for The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
Publicado: (2013)

Long Noncoding RNA ZBED5-AS1 Facilitates Tumor Progression and Metastasis in Lung Adenocarcinoma via ZNF146/ATR/Chk1 Axis
por: Jiang, Feng, et al.
Publicado: (2023)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

APE1 assembles biomolecular condensates to promote the ATR–Chk1 DNA damage response in nucleolus
por: Li, Jia, et al.
Publicado: (2022)

The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis
por: Zahnreich, Sebastian, et al.
Publicado: (2023)

Tim–Tipin dysfunction creates an indispensible reliance on the ATR–Chk1 pathway for continued DNA synthesis
por: Smith, Kevin D., et al.
Publicado: (2009)

An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway
por: Li, Kaiwen, et al.
Publicado: (2020)

The POLD1(R689W) variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors
por: Job, Albert, et al.
Publicado: (2020)

7-Ketocholesterol induces ATM/ATR, Chk1/Chk2, PI3K/Akt signalings, cytotoxicity and IL-8 production in endothelial cells
por: Chang, Mei-Chi, et al.
Publicado: (2016)

ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission
por: Mackay, Douglas R., et al.
Publicado: (2015)

Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation
por: Shen, Tao, et al.
Publicado: (2018)

Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells
por: Mordasini, Vanessa, et al.
Publicado: (2016)

The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion
por: Dembitz, Vilma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_52u76cqu3jogtj6cir7g1vmd89